Filing Details

Accession Number:
0001209191-21-040760
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-06-15 20:03:58
Reporting Period:
2021-06-14
Accepted Time:
2021-06-15 20:03:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1746473 Pliant Therapeutics Inc. PLRX Pharmaceutical Preparations (2834) 474272481
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1808895 Bernard Coulie C/O Pliant Therapeutics, Inc.
260 Littlefield Avenue
South San Francisco CA 94080
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-06-14 3,757 $32.98 449,560 No 4 S Indirect See footnote
Common Stock Disposition 2021-06-14 243 $33.69 449,317 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 54,840 Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020.
  2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.4100 to $33.4000, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
  3. Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.4100 to $33.9500, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.